DUBLIN, Ireland, December 11, 2013 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to its previously announced tender offer by a wholly owned subsidiary of Shire for all outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM) expired at 11:59 p.m., Eastern U.S. time, on December 10, 2013. The expiration of the HSR waiting period satisfies one of the conditions to the tender offer. The tender offer remains subject to certain other conditions set forth in the offer to purchase, including the termination of review or approval of the transaction by the United Kingdom Office of Fair Trading and the satisfaction of the minimum tender condition. The tender offer is scheduled to expire at 6:00 p.m., Eastern U.S. time, on Thursday, December 26, 2013, unless the tender offer is extended.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
http://www.shire.com
Help employers find you! Check out all the jobs and post your resume.
